Why Eli Lilly Topped the Market Today

Published August 10, 2026 · Category: Finance

Overview

Eli Lilly (NYSE: LLY) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided plenty of optimism for these types of drugs, which have been hotly popular for years now.

The product in question is Lilly's Foundayo, its first weight-loss pill (not to be confused with the company's Zepbound, an obesity treatment delivered via injection). On Monday, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved Foundayo for both weight management and type 2 diabetes.

Image source: Getty Images.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• Here’s who stands to gain the most from a Jeff Bezos-Liverpool FC deal
• Amazon.com vs. Chewy: Which Consumer Stock Is a Better Buy in 2026?
• What to Know About This Natera Insider Transaction as Shares Surge to Record Highs